This paper describes the significant developments that have occurred in the last 5 to 10 years in the field of drug precursors related to synthetic stimulant drugs produced in the EU. This includes describing the ‘pre-precursor’ phenomenon and responses to it, both by the EU and by the drug producers themselves. The developments are complex and of a deeply technical nature. This paper will be of particular interest to forensic chemists, investigators or those involved in drug precursor control.
This is a supporting publication to the 2019 EU Drug Markets Report.